Search

Displaying results 4071 - 4080 of 5898 in total
  1. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.

  2. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene. … Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  3. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.

  4. Drug

    EHT899

    go.drugbank.com/drugs/DB05108
    Experimental

    EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. … It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

  5. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

  6. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

  7. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

  8. Drug

    CYP-001

    go.drugbank.com/drugs/DB15739
    Investigational

    These cells are used to treat chronic allergic airway disease and fibrosis, among other pathologies. … These cells are then able to differentiate into bone, cartilage, and adipose tissue. The MCA-derived MSCs can be obtained from induced pluripotent stem cells (iPSCs) and then expanded in media.

  9. Drug

    Vamotinib

    go.drugbank.com/drugs/DB15396
    Investigational

    Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene). … Vamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With

  10. Drug

    AVAC

    go.drugbank.com/drugs/DB05441
    Experimental

    It has been tested in uses related to asthma and in treating eczema and atopic dermatitis. … [Mycobacterium vaccae] is a non-pathogenic, saprophytic bacteria whose antigens can be used to induce peripheral immune activation through the activity of regulatory T-cells that surpress inappropriate